Shares in Hikma soar on impressive half year results and upgraded guidance
Pharmaceutical company Hikma (HIK) beats expectations in the six months to 30 June, prompting an upgrade in guidance for both its injectables and generics businesses.Shares in Hikma have rallied 8.6% to £17.89 on the news.The strong...
15 August 2018